, Tracking Stock Market Picks
Enter Symbol:
Impax Laboratories, Inc. (IPXL) [hlAlert]

down 51.33 %

Impax Laboratories, Inc. (IPXL) rated Underperform by Buckingham Research

Posted on: Monday,  Aug 12, 2013  9:25 AM ET by Buckingham Research

Buckingham Research rated Underperform Impax Laboratories, Inc. (NASDAQ: IPXL) on 08/12/2013, when the stock price was $21.40. Since
then, Impax Laboratories, Inc. has gained 105.47% as of 01/20/2016's recent price of $43.97.
If you would have followed this Buckingham Research's recommendation on IPXL, you would have lost 51.33% of your investment in 891 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Buckingham Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/12/2013 9:25 AM Sell
as of 12/13/2013
1 Week up  3.25 %
1 Month up  2.80 %
3 Months down  -10.99 %
1 YTD down  -7.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy